SenzaGen has received another project to test chemicals with GARD®skin and GARD®potency worth around SEK 0.7 million. The project is a follow-on order from collaboration initiated in 2020 with one of the leading US-based chemicals companies with global operations, which demonstrates how much customers value the Company's tests. The tests will be performed at SenzaGen’s GLP-certified laboratory in Lund. The agreement includes an option for more tests in 2022.
The customer has a global presence and its headquarters are located in the US. The corporation has a rich tradition of innovation with a world-leading range of products and technology. The new order is the result of successful evaluation of GARD during 2020-2021 and is linked to one of the company's research and development projects.
“We are delighted to have received this follow-on order, which confirms the reliability and performance of our GARD® technology for chemical risk assessment. A decisive factor for this order was the unique capability of GARD® to support complex mixtures and, when needed, provide information on whether the allergenicity of the substances is strong or weak. The project is fully in line with our commercial focus and the customer’s commitment to the Three Rs: reduce, refine, and replace animals in allergy testing. Working with this type of global customer is how we build credibility and lay the foundation for value creation and future growth,” says Peter Nählstedt, President and CEO of SenzaGen.
SenzaGen’s GARD® test platform is designed for companies looking to increase the accuracy of their test results and ensure product safety while avoiding animal studies. The platform combines genomic data from human cells with machine learning, making the method both more effective and more accurate than traditional animal-based methods, including for formulations that are traditionally considered difficult to assess.